Bionano Genomics 4,45USD +3,90USD +708,21%

https://www.marketbeat.com/stocks/NASDAQ/BNGO/price-target/

https://www.analystratings.com/articles/...-genomics-nasdaq-bngo/amp/  

Schwer zu glauben, die fällt und fällt...hört hat nicht mehr auf...  

12USD? Bon der Zahl entfernt die sich aber immer weiter. Die Aktie wird wohl als Leiche bei mir im Depot bleiben :(  

 

The Trade: Bionano Genomics, Inc. (NASDAQ:BNGO) President and CEO R. Erik Holmlin acquired a total of 5025 shares at an average price of $3.99. The insider spent $20,037.25 to buy those shares.
What’s Happening: On CNBC’s "Mad Money Lightning Round," Jim Cramer said Bionano Genomics is a good spec, but he actually likes CRISPR Therapeutics.
What Bionano Genomics Does: Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space.

https://www.benzinga.com/amp/content/24380684  

https://investorplace.com/2021/12/...tics-are-wrong-about-bngo-stock/  

•Oppenheimer says that Bionano Genomics (NASDAQ:BNGO) is a buy due to strong 2021 sales of its Saphyr System for genome imaging.

•The firm has a $14 price target on shares (332% upside based on Thursday's close).

•Analyst Kevin DeGeeter says that his estimate is for Bionano to place 156 Saphyr Systems this year, above the 150 target set by the company.

•Multiple clinical validation studies to support reimbursement are enrolling well and commercial adoption is leading to higher consumable pull-through that should impact 4Q21 and 2022," he writes.

https://seekingalpha.com/amp/news/...ic-mapping-sales-sees-332-upside

 

 

Lest mal den unten verlinkten Artikel.

Selbst wenn der Umsatz x10 in 2022 sein sollte würde die Aktie um 7$ wert sein (lt. dem Link)

https://seekingalpha.com/article/...lab-than-marketing-saphyr-success

Was meint ihr dazu? Meine haben sich zu einer Leichte im Depo entwickelt, leider.  

oder Leiche? Leiche trifft es bei mir auch ganz gut. Auf Kursziele gebe ich nichts mehr. Wenn das Marktumfeld negativ ist, können die schreiben was sie wollen  

BIONANO GENOMICS REPORTS PRELIMINARY FOURTH QUARTER AND FULL-YEAR 2021 RESULTS

- Preliminary Q4 revenue expected between $5.8 and $6.2 million; 45%-55% increase over Q4 2020

- Reached installed base of 164 systems: 69% increase over YE 2020

- Achieved or exceeded all stated goals and milestones for the full year 2021

https://ir.bionanogenomics.com/news-releases/...urth-quarter-and-full

 

Was man so liest so schlecht nicht das abgelaufene Jahr für Bionano.  

Sehe ich genauso, sollte den Kurs stabilisieren  und hoffentlich die Trendumkehr einläuten.  

https://www.tipranks.com/news/article/...PL2wYjANYGMymn2f5yvBRjGC6roM  

https://ir.bionanogenomics.com/news-releases/...er-and-full-year-2021  

Bionano Genomics Announces Publication of Comprehensive Validation of Optical Genome Mapping for Hematologic Neoplasms

Key findings from evaluation of 59 Heme Samples and 10 Controls:

OGM detected 162/164 SVs detected by standard cytogenetics methods of karyotyping and FISH

OGM detected chromosomal aberrations missed by karyotyping and FISH in 35 cases

OGM Sensitivity: 98.7%

OGM Specificity: 100%

Positive Predictive Value: 100%

Negative Predictive Value: 98%

OGM Accuracy: 99.2%

First-Pass Success Rate: 100%

Limit of Detection (LOD) for aneuploidies, translocations, interstitial deletions and duplications at 400X: 5% variant allele fraction

Key findings from evaluation of 59 Heme Samples and 10 Controls:

•OGM detected 162/164 SVs detected by standard cytogenetics methods of karyotyping and FISH

•OGM detected chromosomal aberrations missed by karyotyping and FISH in 35 cases

•OGM Sensitivity: 98.7%

•OGM Specificity: 100%

•Positive Predictive Value: 100%

•Negative Predictive Value: 98%

•OGM Accuracy: 99.2%

•First-Pass Success Rate: 100%

•Limit of Detection (LOD) for aneuploidies, translocations, interstitial deletions and duplications at 400X: 5% variant allele fraction

https://finance.yahoo.com/news/...cation-comprehensive-120000033.html  

https://stocktwits.com/Austinbaby84/message/447237567  

Bionano to Accelerate Data Processing Solution for Optical Genome Mapping Workflow with NVIDIA

https://finance.yahoo.com/news/...-processing-solution-130000604.html  

Optimal genome mapping offers high-resolution method to better see, then target cancer-causing gene variants

...The standardization of the technique was necessary to establish precisely how to use OGM on patients to obtain consistently, accurate results.

Other investigators also have been exploring OGM's potential in specific cancers like acute lymphoblastic leukemias and larger groups of cancer types as well.

There already is some movement in places like Europe and Canada to move away from longtime approaches like FISH and move toward OGM. Kolhe hopes the newly published information about how to use OGM for patients will help do the same in this country.

Later this month, the Georgia Cancer Center will be the first to use OGM for patient care in the United States, Kolhe says. While many centers do not have the OGM technology, providers can send their patients' cells to MCG's Georgia Esoteric and Molecular Lab for testing effectively immediately...

https://www.sciencedaily.com/releases/2023/01/...w7mM0GonTy_-L2ebY79Q  

 

Recht ordentliche Stückzahlen in den USA, aber der Kursverlauf ist nicht berauschend.

Ist hier viel Zukunftsmusik oder in absehbarer Zeit ein profitables Unternehmen zu erwarten?  

scheint die Firma ganz gut zu kennen. Ich bin seit 1 1/2 Jahren mit ner kleinen Stückzahl investiert. 200 Stück  

nicht schlecht. Verstehe den Abverkauf nicht.
https://ir.bionanogenomics.com/news-releases/...er-and-full-year-2022  

die vorherigen Unternehmensmeldungen empfand ich als Laie positiv, aber der Kurs sackt stetig ab. Für unprofitable Wachstumsunternehmen ist das Umfeld ja grundsätzlich schlecht. Ob die Umsätze und Kosten sich schlechter als erwartet entwickelt haben, habe ich noch nicht gelesen.  

fällt und fällt.......